Figure 2.

Prognostic performance of the 8-CpGs RISK score signature (a) in two discovery cohorts of non-G-CIMP GBMs, one with RT/TMZ (RAUH-GSE22891), and the other with both RT/TMZ and RT monotherapy (TCGA-GBM); (b) in four independent validation cohorts of non-G-CIMP GBMs, including RAUH-new cohort with RT/TMZ, GSE50923 with RT/TMZ, GSE60274 with both RT/TMZ and RT monotherapy, and GSE36278 with unknown regimens. Prognostic performance of the 8-CpGs RISK score signature in terms of PFS outcome (c) in RAUH-new cohort; (d) RISK scores in non-G-CIMP GBMs (grade IV), IDHwt LGGs (grade II to III), and NTBs; Prognostic performance of the 8-CpGs RISK score signature (e) in two independent validation cohorts of IDHwt LGGs, including GSE48462 with RT/PCV and RT monotherapy and TCGA-LGGs with various regimens; * indicates p value for TCGA G2 vs. TCGA NTB (or GSE63347 NTB) < 0.05; OS = overall survival; PFS = progression-free survival; G-CIMP = glioma-CpG island methylator phenotype; IDHwt = IDH wild type; GBM = glioblastoma; LGG = lower-grade glioma; RT = radiotherapy; TMZ = temozolomide; PCV = procarbazine, lomustine, and vincristine; NTBs = non-tumor brains